Adagrasib-cetuximab combination shows promising results in treating KRAS G12C-mutated colorectal cancer, with FDA Breakthrough Therapy designation.
Adagrasib (Krazati) combined with cetuximab showed promising results in a Phase 1/2 study for treating previously treated KRAS G12C-mutated locally advanced or metastatic colorectal cancer. The combination demonstrated an overall response rate of 34%, median progression-free survival of 6.9 months, and median overall survival of 15.9 months. The FDA has granted Breakthrough Therapy designation to this combination.
April 08, 2024
6 Articles